Sponsor content
37 result(s) found, displaying 1 to 10
-
Australian public assessment report (AusPar)Epyztek (ustekinumab) is approved for treatment of several conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
-
Australian public assessment report (AusPar)Ospomyv, Xborso (denosumab) have been approved for the prevention and treatment of multiple bone-related pathologies.
-
Australian public assessment report (AusPar)Opuviz, a bioisimilar to Eylea, has been approved for multiple eye-related conditions.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OPUVIZ aflibercept 40 mg/mL solution for intravitreal injection in vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OPUVIZ aflibercept 40 mg/mL solution for intravitreal injection in vial with needle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OSPOMYV denosumab 60mg/1mL solution for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for XBORSO denosumab 120mg/1.7mL solution for injection vial.
-
Prescription medicine registrationActive ingredients: Aflibercept.
-
Prescription medicine registrationActive ingredients: Denosumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for EPYZTEK ustekinumab 45 mg/0.5mL solution for injection pre-filled syringe.